$308.07
0.88% yesterday
Nasdaq, May 13, 10:00 pm CET
ISIN
US91307C1027
Symbol
UTHR

United Therapeutics Corporation Stock price

$308.07
+23.76 8.36% 1M
-92.38 23.07% 6M
-44.77 12.69% YTD
+43.73 16.54% 1Y
+124.63 67.94% 3Y
+194.99 172.44% 5Y
+132.60 75.57% 10Y
Nasdaq, Closing price Tue, May 13 2025
-2.73 0.88%
ISIN
US91307C1027
Symbol
UTHR
Sector
Industry

Key metrics

Market capitalization $13.90b
Enterprise Value $10.77b
P/E (TTM) P/E ratio 12.29
EV/FCF (TTM) EV/FCF 9.57
EV/Sales (TTM) EV/Sales 3.60
P/S ratio (TTM) P/S ratio 4.64
P/B ratio (TTM) P/B ratio 2.04
Revenue growth (TTM) Revenue growth 19.85%
Revenue (TTM) Revenue $2.99b
EBIT (operating result TTM) EBIT $1.40b
Free Cash Flow (TTM) Free Cash Flow $1.13b
Cash position $3.32b
EPS (TTM) EPS $25.06
P/E forward 11.31
P/S forward 4.30
EV/Sales forward 3.34
Short interest 5.73%
Show more

Is United Therapeutics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

United Therapeutics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a United Therapeutics Corporation forecast:

9x Buy
60%
6x Hold
40%

Analyst Opinions

15 Analysts have issued a United Therapeutics Corporation forecast:

Buy
60%
Hold
40%

Financial data from United Therapeutics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,994 2,994
20% 20%
100%
- Direct Costs 329 329
18% 18%
11%
2,665 2,665
20% 20%
89%
- Selling and Administrative Expenses 658 658
37% 37%
22%
- Research and Development Expense 526 526
23% 23%
18%
1,481 1,481
13% 13%
49%
- Depreciation and Amortization 77 77
41% 41%
3%
EBIT (Operating Income) EBIT 1,404 1,404
12% 12%
47%
Net Profit 1,211 1,211
15% 15%
40%

In millions USD.

Don't miss a Thing! We will send you all news about United Therapeutics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

United Therapeutics Corporation Stock News

Positive
MarketBeat
12 days ago
A reclusive firm is often considered the world's most successful hedge fund. That company is Renaissance Technologies.
Neutral
Seeking Alpha
14 days ago
United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2025 Earnings Conference Call April 30, 2025 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer Leigh Peterson - Executive Vice President, Product Development and Xenotransplantation James Edgemond - Chief Fi...
Neutral
Business Wire
14 days ago
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. “2025 is off to a tremen...
More United Therapeutics Corporation News

Company Profile

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Head office United States
CEO Martine Rothblatt
Employees 1,305
Founded 1996
Website www.unither.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today